Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Gastrointestinal stromal tumors, somatic mutations and candidate genetic risk variants.

O'Brien KM, Orlow I, Antonescu CR, Ballman K, McCall L, DeMatteo R, Engel LS.

PLoS One. 2013 Apr 18;8(4):e62119. doi: 10.1371/journal.pone.0062119. Print 2013.

2.

Tyrosine-kinase mutations in c-KIT and PDGFR-alpha genes of imatinib naïve adult patients with gastrointestinal stromal tumours (GISTs) of the stomach and small intestine: relation to tumour-biological risk-profile and long-term outcome.

Søreide K, Sandvik OM, Søreide JA, Gudlaugsson E, Mangseth K, Haugland HK.

Clin Transl Oncol. 2012 Aug;14(8):619-29. doi: 10.1007/s12094-012-0851-x. Epub 2012 Jul 18.

PMID:
22855146
3.
4.

KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs).

Lasota J, Miettinen M.

Semin Diagn Pathol. 2006 May;23(2):91-102. Review.

PMID:
17193822
5.

Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.

Joensuu H, Wardelmann E, Sihto H, Eriksson M, Sundby Hall K, Reichardt A, Hartmann JT, Pink D, Cameron S, Hohenberger P, Al-Batran SE, Schlemmer M, Bauer S, Nilsson B, Kallio R, Junnila J, Vehtari A, Reichardt P.

JAMA Oncol. 2017 May 1;3(5):602-609. doi: 10.1001/jamaoncol.2016.5751.

PMID:
28334365
6.

Practical role of mutation analysis for imatinib treatment in patients with advanced gastrointestinal stromal tumors: a meta-analysis.

Zhi X, Zhou X, Wang W, Xu Z.

PLoS One. 2013 Nov 4;8(11):e79275. doi: 10.1371/journal.pone.0079275. eCollection 2013.

7.

Molecular characterization of an Italian series of sporadic GISTs.

Origone P, Gargiulo S, Mastracci L, Ballestrero A, Battistuzzi L, Casella C, Comandini D, Cusano R, Dei Tos AP, Fiocca R, Garuti A, Ghiorzo P, Martinuzzi C, Toffolatti L; Liguria GIST Unit, Bianchi Scarrà G.

Gastric Cancer. 2013 Oct;16(4):596-601. doi: 10.1007/s10120-012-0213-y. Epub 2013 Jan 5.

PMID:
23291969
8.

Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.

Agaram NP, Wong GC, Guo T, Maki RG, Singer S, Dematteo RP, Besmer P, Antonescu CR.

Genes Chromosomes Cancer. 2008 Oct;47(10):853-9. doi: 10.1002/gcc.20589.

9.

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA.

J Clin Oncol. 2003 Dec 1;21(23):4342-9.

PMID:
14645423
10.

High-resolution melting analysis is a sensitive diagnostic tool to detect imatinib-resistant and imatinib-sensitive PDGFRA exon 18 mutations in gastrointestinal stromal tumors.

Künstlinger H, Binot E, Merkelbach-Bruse S, Huss S, Wardelmann E, Buettner R, Schildhaus HU.

Hum Pathol. 2014 Mar;45(3):573-82. doi: 10.1016/j.humpath.2013.10.025. Epub 2013 Nov 4.

PMID:
24444465
11.

Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors.

Lim KH, Huang MJ, Chen LT, Wang TE, Liu CL, Chang CS, Liu MC, Hsieh RK, Tzen CY.

Med Oncol. 2008;25(2):207-13. doi: 10.1007/s12032-007-9014-2. Epub 2007 Oct 6.

PMID:
18488160
12.

KIT, PDGFRA, and BRAF mutational spectrum impacts on the natural history of imatinib-naive localized GIST: a population-based study.

Rossi S, Gasparotto D, Miceli R, Toffolatti L, Gallina G, Scaramel E, Marzotto A, Boscato E, Messerini L, Bearzi I, Mazzoleni G, Capella C, Arrigoni G, Sonzogni A, Sidoni A, Mariani L, Amore P, Gronchi A, Casali PG, Maestro R, Dei Tos AP.

Am J Surg Pathol. 2015 Jul;39(7):922-30. doi: 10.1097/PAS.0000000000000418.

PMID:
25970686
13.

Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.

Yeh CN, Chen TW, Lee HL, Liu YY, Chao TC, Hwang TL, Jan YY, Chen MF.

Ann Surg Oncol. 2007 Mar;14(3):1123-8. Epub 2006 Dec 31.

PMID:
17195905
14.

Gastrointestinal stromal tumors with KIT exon 9 mutations: Update on genotype-phenotype correlation and validation of a high-resolution melting assay for mutational testing.

Künstlinger H, Huss S, Merkelbach-Bruse S, Binot E, Kleine MA, Loeser H, Mittler J, Hartmann W, Hohenberger P, Reichardt P, Büttner R, Wardelmann E, Schildhaus HU.

Am J Surg Pathol. 2013 Nov;37(11):1648-59. doi: 10.1097/PAS.0b013e3182986b88.

PMID:
24061512
15.

microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome.

Akçakaya P, Caramuta S, Åhlen J, Ghaderi M, Berglund E, Östman A, Bränström R, Larsson C, Lui WO.

Br J Cancer. 2014 Nov 25;111(11):2091-102. doi: 10.1038/bjc.2014.548. Epub 2014 Oct 30.

16.

One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.

Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Monge OR, Bono P, Kallio R, Vehtari A, Leinonen M, Alvegård T, Reichardt P.

JAMA. 2012 Mar 28;307(12):1265-72. doi: 10.1001/jama.2012.347.

PMID:
22453568
17.

Molecular alterations and expression of succinate dehydrogenase complex in wild-type KIT/PDGFRA/BRAF gastrointestinal stromal tumors.

Celestino R, Lima J, Faustino A, Vinagre J, Máximo V, Gouveia A, Soares P, Lopes JM.

Eur J Hum Genet. 2013 May;21(5):503-10. doi: 10.1038/ejhg.2012.205. Epub 2012 Sep 5.

18.

KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence.

Joensuu H, Rutkowski P, Nishida T, Steigen SE, Brabec P, Plank L, Nilsson B, Braconi C, Bordoni A, Magnusson MK, Sufliarsky J, Federico M, Jonasson JG, Hostein I, Bringuier PP, Emile JF.

J Clin Oncol. 2015 Feb 20;33(6):634-42. doi: 10.1200/JCO.2014.57.4970. Epub 2015 Jan 20.

PMID:
25605837
19.

[Molecular and genetic features of gastrointestinal stromal tumors (GIST)].

Buleje S J, Yábar B A, Guevara-Fujita M, Fujita R.

Rev Gastroenterol Peru. 2012 Oct-Dec;32(4):394-9. Review. Spanish.

PMID:
23307090
20.

ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression.

Van den Abbeele AD, Gatsonis C, de Vries DJ, Melenevsky Y, Szot-Barnes A, Yap JT, Godwin AK, Rink L, Huang M, Blevins M, Sicks J, Eisenberg B, Siegel BA.

J Nucl Med. 2012 Apr;53(4):567-74. doi: 10.2967/jnumed.111.094425. Epub 2012 Mar 1.

Supplemental Content

Support Center